GC Rising Baseline
GC RIsing
The answer to the following question was provided by LCGC’s “GC Connections” columnist John Hinshaw.
Q: In gas chromatography, why might a rising baseline be observed when using temperature gradients?
John Hinshaw: Baseline rise during a temperature program can be attributed to three principal effects. First, at higher temperatures the stationary phase can vaporize slightly or may decompose under the influence of temperature, the presence of oxygen traces in the carrier gas, or due to catalytic decomposition from sample residues. This will cause the detector to respond. Stationary phase bleed may be identified with a GC–MS system by the presence of SiO- fragments in the mass spectrum.
A second cause of stationary phase bleed is the decomposition of sample residues themselves to produce a gradually increasing baseline during a temperature program. In both of these cases the bleed will tend to decrease once an isothermal final temperature is reached due to depletion of the source of the bleed.
The third cause is a change in the mass flow of the carrier gas from not using a constant flow mode. As temperatures increase the carrier gas viscosity increases as well, causing the flow to drop off if the pressure drop is held constant. The constant flow mode increases the pressure drop to compensate.
Many detectors are sensitive to the carrier flow; in a mass spectrometer the detector sensitivity may also be affected as the source pressure drops slightly during a temperature program. If hydrogen carrier is used then the total hydrogen flow through the detector will change without constant flow, potentially causing a shift in response factors with hydrogen-consuming detectors such as the FID.
If you have a question you'd like answered, please submit them at Ask LCGC. We look forward to hearing from you!
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
